<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639246</url>
  </required_header>
  <id_info>
    <org_study_id>AVB500-OC-002</org_study_id>
    <nct_id>NCT03639246</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer</brief_title>
  <official_title>A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination With Pegylated Liposomal Doxorubicin (PLD) or Paclitaxel (Pac) in Patients With Platinum-resistant Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aravive, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aravive, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2 study of AVB-S6-500 in combination with pegylated liposomal doxorubicin&#xD;
      (PLD) or paclitaxel (Pac) in patients with platinum resistant recurrent ovarian cancer. The&#xD;
      phase 1b portion of the study is open label and patients will receive either AVB-S6-500+PLD&#xD;
      or AVB-S6-500+ Pac. The Phase 2 portion of the study is randomized, double-blind,&#xD;
      placebo-controlled study to compare efficacy and tolerability of AVB-S6-500 in combination&#xD;
      with PLD or Pac versus placebo plus PLD or Pac.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While this study was planned as two-part study consisting of a Phase 1b and a Phase 2&#xD;
      portion, the sponsor decided not to proceed with the Phase 2 portion.&#xD;
&#xD;
      The Phase 1b portion of the study was a multicenter, 2-group, open-label design to evaluate&#xD;
      the safety and tolerability of AVB-S6-500 combined with PLD or Pac in subjects with&#xD;
      platinum-resistant recurrent ovarian cancer. The decision to enroll in the Phase 2 portion of&#xD;
      the study was to be driven by the recommendation of a safe and tolerable dose of AVB-S6-500&#xD;
      in combination with each chemotherapy backbone; however, enrollment into the Phase 2 portion&#xD;
      was not initiated per Sponsor decision. Given that sufficient data were obtained in the Phase&#xD;
      1b portion AVB-S6-500 + Pac group, the decision was made to pursue a randomized Phase 3 to&#xD;
      further study the benefit of this combination versus paclitaxel alone in patients with&#xD;
      platinum resistant ovarian cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 6, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">January 8, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by the number of patients with AEs in Phase 1 portion of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-tumor activity of AVB-S6-500 in combination with PLD</measure>
    <time_frame>18 months</time_frame>
    <description>Measured by progression free survival (PFS) in patients receiving AVB-S6-500+PLD versus patients receiving Placebo+PLD in Phase 2 portion of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-tumor activity of AVB-S6-500 in combination with Pac</measure>
    <time_frame>18 months</time_frame>
    <description>Measured by progression free survival (PFS) in patients receiving AVB-S6-500+ Pac versus patients receiving Placebo+Pac in Phase 2 portion of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC</measure>
    <time_frame>18 months</time_frame>
    <description>Area under the AVB-S6-500 concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax</measure>
    <time_frame>18 months</time_frame>
    <description>Maximum observed AVB-S6-500 concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Tmax</measure>
    <time_frame>18 months</time_frame>
    <description>Time of maximum observed AVB-S6-500 concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: t1/2</measure>
    <time_frame>18 months</time_frame>
    <description>Apparent terminal half-life of AVB-S6-500.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic marker assessment</measure>
    <time_frame>18 months</time_frame>
    <description>Change from the baseline in GAS6 serum levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody (ADA) titers</measure>
    <time_frame>18 months</time_frame>
    <description>Change from baseline in ADA titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>18 months</time_frame>
    <description>Proportion of subjects who have a partial or complete response to therapy relative to baseline as assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as well as Gynecologic Cancer Intergroup (GCIG) cancer antigen (CA)-125 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>18 months</time_frame>
    <description>Proportion of subjects who have a complete or partial response to therapy or maintain stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>18 months</time_frame>
    <description>Measured from the date of partial or complete response to therapy until the cancer progresses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>30 months</time_frame>
    <description>Time following the treatment until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA-125 response rate</measure>
    <time_frame>18 months</time_frame>
    <description>Proportion of subjects with a minimum 50% reduction in CA-125 serum levels lasting for 28 days relative to baseline CA-125 serum levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life(QOL)</measure>
    <time_frame>18 months</time_frame>
    <description>Subject QOL will be assessed every 8 weeks during treatment using the Functional Assessment Of Cancer Therapy - Ovarian Cancer (FACT-O) questionnaire, which consists of 4 subscales: physical well-being (7 questions), social/family well-being (7 questions), emotional well-being (6 questions), and functional well-being (7 questions), and 12 additional concerns specific to ovarian cancer. All items are rated on a 5 point scale with 0 &quot;not at all&quot; and 4 &quot;very much&quot;. The scoring algorithm allows for eight summary scales: the four core well-being subscales, a subtotal of the 27 core items, a subtotal of the 12 ovarian-specific additional concerns, a grand total of the 39 items, and a trial outcome index (sum of the 17 physical and functional wellbeing items plus the 12 ovarian-specific items).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1b: AVB-S6-500+PLD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: AVB-S6-500+Pac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: AVB-S6-500+PLD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: AVB-S6-500+Pac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Placebo+PLD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Placebo+Pac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVB-S6-500</intervention_name>
    <description>AVB-S6-500 is experimental drug</description>
    <arm_group_label>Phase 1b: AVB-S6-500+PLD</arm_group_label>
    <arm_group_label>Phase 1b: AVB-S6-500+Pac</arm_group_label>
    <arm_group_label>Phase 2: AVB-S6-500+PLD</arm_group_label>
    <arm_group_label>Phase 2: AVB-S6-500+Pac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel (Pac)</intervention_name>
    <description>Paclitaxel is active comparator</description>
    <arm_group_label>Phase 1b: AVB-S6-500+Pac</arm_group_label>
    <arm_group_label>Phase 2: AVB-S6-500+Pac</arm_group_label>
    <arm_group_label>Phase 2: Placebo+Pac</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated liposomal doxorubicin (PLD)</intervention_name>
    <description>PLD is active comparator</description>
    <arm_group_label>Phase 1b: AVB-S6-500+PLD</arm_group_label>
    <arm_group_label>Phase 2: AVB-S6-500+PLD</arm_group_label>
    <arm_group_label>Phase 2: Placebo+PLD</arm_group_label>
    <other_name>Doxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Phase 2: Placebo+PLD</arm_group_label>
    <arm_group_label>Phase 2: Placebo+Pac</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Histologically confirmed and documented recurrent ovarian, fallopian tube, and&#xD;
             peritoneal cancer.&#xD;
&#xD;
          -  Platinum resistant disease, defined as progression within â‰¤ 6 months from completion&#xD;
             of most recent regimen and calculated from the date of the last administered dose of&#xD;
             platinum therapy&#xD;
&#xD;
          -  Must have available archived tumor tissue OR if archived tissue is not available,&#xD;
             willing to provide a fresh tumor biopsy&#xD;
&#xD;
          -  Must have radiologic imaging with a computerized tomography (CT) scan or magnetic&#xD;
             resonance imaging (MRI) within 4 weeks of first dose of study drug&#xD;
&#xD;
          -  Received at least 1 but not more than 3 therapy regimens, not including maintenance or&#xD;
             adjuvant therapy&#xD;
&#xD;
          -  Must have ovarian cancer that is measurable according to RECIST 1.1&#xD;
&#xD;
          -  ECOG performance status of 0-1&#xD;
&#xD;
          -  Normal gastrointestinal (GI), bone marrow, liver and kidney function&#xD;
&#xD;
          -  At least 28 days between termination of prior anti-cancer or hormonal therapy and&#xD;
             administration of AVB-S6-500&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary platinum-refractory disease (defined as progression during the first platinum&#xD;
             regimen or within 4 weeks of completion of the first platinum regimen)&#xD;
&#xD;
          -  Currently being treated with concurrent anti-cancer therapy or any other&#xD;
             interventional treatment or trial&#xD;
&#xD;
          -  Received prior therapy with Pac or PLD in the recurrent setting, depending on&#xD;
             physician-chosen chemotherapy for this study&#xD;
&#xD;
          -  Significant cardiac disease history&#xD;
&#xD;
          -  Has other prior or concurrent malignancy within the past 5 years except adequately&#xD;
             treated basal cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  Symptomatic CNS metastasis or metastases&#xD;
&#xD;
          -  Serious active infection requiring IV antibiotics and/or hospitalization at study&#xD;
             entry&#xD;
&#xD;
          -  Has known previous or current human immune deficiency (HIV) syndrome, hepatitis B, or&#xD;
             hepatitis C&#xD;
&#xD;
          -  Has had paracentesis for ascites within 3 months&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Jo Baker</last_name>
    <role>Study Director</role>
    <affiliation>Aravive Biologics Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Oncology</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Roseville</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Santa Clara</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Vallejo</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Walnut Creek</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OUHSC-Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute and Research Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin Central</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - San Antonio Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian cancer</keyword>
  <keyword>Platinum resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

